account_balance
Investment manager · 13F filer · SEC CIK 2010850
Decheng Capital LLC
Reported value$732Mas of Jun 30, 2026
Positions14 1 new, 1 sold out
Top 10 weight98.1%CGON alone is 62%
FiledAug 1445 days after quarter end
Portfolio · as of Jun 30, 2026
Where the money is
New or addedTrimmedHeld
CGONCg Oncology Inc
61.9%
NUVBNuvation Bio Inc.
20.1%
AARDAardvark Therapeutics Inc
3.1%
ACRSAclaris Therapeutics, Inc.
2.9%
UPBUpstream Bio Inc.
2.6%
RCUSArcus Biosciences, Inc
2.0%Trimmed −3%
EQEquillium Inc.
1.9%
RVMD1.3%Lyell Immunopharma, Inc.1.3%
BYSI0.9%ZNTL0.9%NAMS0.8%Boxes show the top 12 stocks, sized against each other. The bar above shows how much of the fund they are. 13F only covers US-listed stocks, so foreign holdings and short positions are missing.
Show the top 12 as a list
CGON Cg Oncology Inc 61.9% HeldNUVB Nuvation Bio Inc. 20.1% HeldAARD Aardvark Therapeutics Inc 3.1% HeldACRS Aclaris Therapeutics, Inc. 2.9% HeldUPB Upstream Bio Inc. 2.6% HeldRCUS Arcus Biosciences, Inc 2.0% Trimmed −3%EQ Equillium Inc. 1.9% HeldRVMD Revolution Medicines Inc(nsm) 1.3% Trimmed −44%
Lyell Immunopharma, Inc. 1.3% Held
BYSI BeyondSpring Inc. 0.9% HeldZNTL Zentalis Pharmaceuticals Inc. 0.9% HeldNAMS Newamsterdam Pharma Co NV 0.8% Trimmed −46%What changed